A.P. Pharma Announces Positive Phase 3 Results With APF530 In The Prevention Of Chemotherapy Induced Nausea And Vomiting

A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, announced today positive results from its pivotal Phase 3 study comparing te efficacy of APF530 (the Company's proprietary, sustained release formulation of granisetron) with Aloxi^ for the prevention of chemotherapy induced nausea and vomiting (CINV).